• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New approaches to the endocrine prevention and treatment of breast cancer.

作者信息

Howell Anthony, Howell Sacha J, Evans D Gareth

机构信息

CRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK.

出版信息

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S39-44. doi: 10.1007/s00280-003-0645-5. Epub 2003 Jun 18.

DOI:10.1007/s00280-003-0645-5
PMID:12819938
Abstract

All major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.

摘要

相似文献

1
New approaches to the endocrine prevention and treatment of breast cancer.
Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S39-44. doi: 10.1007/s00280-003-0645-5. Epub 2003 Jun 18.
2
The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.STAR试验：雷洛昔芬作为绝经后女性降低乳腺癌风险药物的证据。
J Natl Compr Canc Netw. 2007 Sep;5(8):719-24.
3
Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.在乳腺癌风险增加的绝经后女性中，选择性雌激素受体调节剂治疗的风险、益处及对生活质量的影响。
Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af.
4
Raloxifene (Evista) for breast cancer prevention in postmenopausal women.雷洛昔芬（易维特）用于绝经后女性预防乳腺癌。
Med Lett Drugs Ther. 2006 May 8;48(1234):37.
5
Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.芳香化酶抑制剂用于乳腺癌预防的3期试验：沿着选择性雌激素受体调节剂的道路前行。
Ann N Y Acad Sci. 2009 Feb;1155:141-61. doi: 10.1111/j.1749-6632.2009.03688.x.
6
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.预防激素依赖性癌症（乳腺癌和前列腺癌）的激素干预措施。
Eur J Cancer Prev. 2007 Jun;16(3):232-42. doi: 10.1097/CEJ.0b013e328011ed2d.
7
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.优化内分泌方法以进行乳腺癌化学预防，超越他莫昔芬与雷洛昔芬研究（STAR）试验。
Eur J Cancer. 2006 Nov;42(17):2909-13. doi: 10.1016/j.ejca.2006.09.012. Epub 2006 Oct 24.
8
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).使用选择性雌激素受体调节剂（SERM）预防乳腺癌。
Breast Cancer Res. 2006;8(5):111. doi: 10.1186/bcr1601.
9
Prevention of hormone-related cancers: breast cancer.激素相关癌症的预防：乳腺癌
J Clin Oncol. 2005 Jan 10;23(2):357-67. doi: 10.1200/JCO.2005.08.028.
10
[Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].乳腺癌的化学预防。药物预防的临床试验
Medicina (B Aires). 2004;64(1):66-72.

引用本文的文献

1
Targeting protein quality control pathways in breast cancer.靶向乳腺癌中的蛋白质质量控制通路。
BMC Biol. 2017 Nov 16;15(1):109. doi: 10.1186/s12915-017-0449-4.
2
Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.17-去氢表雄酮葡萄糖醛酸苷的特征：UGT2B17 缺失在依西美坦药物遗传学中的潜在作用。
Pharmacogenet Genomics. 2010 Oct;20(10):575-85. doi: 10.1097/FPC.0b013e32833b04af.
3
Protacs for treatment of cancer.蛋白水解靶向嵌合体用于癌症治疗。
Pediatr Res. 2010 May;67(5):505-8. doi: 10.1203/PDR.0b013e3181d35017.
4
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.UGT 药物遗传学在癌症治疗和预防中的潜在作用：以他莫昔芬和芳香酶抑制剂为例。
Drug Metab Rev. 2010 Feb;42(1):182-94. doi: 10.3109/03602530903208652.
5
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.尿苷二磷酸葡萄糖醛酸转移酶药物遗传学在癌症治疗和预防中的潜在作用：聚焦于他莫昔芬
Ann N Y Acad Sci. 2009 Feb;1155:99-111. doi: 10.1111/j.1749-6632.2009.04114.x.
6
Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.UDP-葡萄糖醛酸基转移酶变体在活性他莫昔芬代谢产物代谢中的功能意义。
Cancer Res. 2009 Mar 1;69(5):1892-900. doi: 10.1158/0008-5472.CAN-08-3708. Epub 2009 Feb 24.
7
Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.人UGT1A4变体对他莫昔芬和4-羟基他莫昔芬葡萄糖醛酸化的表征
Breast Cancer Res. 2006;8(4):R50. doi: 10.1186/bcr1539.
8
Chemical approaches to controlling intracellular protein degradation.控制细胞内蛋白质降解的化学方法。
Chembiochem. 2005 Jan;6(1):40-6. doi: 10.1002/cbic.200400274.